Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes

European Journal of Internal Medicine

Volumn 21, Issue 4, 2010, Pages 254-259

  Mannucci, Pier Mannuccio ^a   Franchini, Massimo ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Acute coronary syndromes; Bleeding; Blood transfusion; Hemostatic agents

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; APROTININ; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DESMOPRESSIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; TRANEXAMIC ACID; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; CLINICAL PRACTICE; COMORBIDITY; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED PRACTICE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GLANZMANN DISEASE; HEART INFARCTION; HEART RATE; HEART SURGERY; HEMATOCRIT; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INVASIVE PROCEDURE; KIDNEY FAILURE; LOADING DRUG DOSE; OFF LABEL DRUG USE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; REPEATED DRUG DOSE; REVIEW; RISK; SCORING SYSTEM; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURGICAL PATIENT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VON WILLEBRAND DISEASE; BLOOD; BLOOD COAGULATION DISORDERS; COMPLICATION; FEMALE; HEMORRHAGE; MALE;

ACUTE CORONARY SYNDROME; BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE;

EID: 77955334532     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.03.010     Document Type: Short Survey

References (45)

1. M. Franchini, and P.M. Mannucci New antiplatelet agents: why they are needed Eur J Intern Med 20 2009 733 738
2. M. Franchini, and P.M. Mannucci A new era for anticoagulants Eur J Intern Med 20 2009 562 568
3. P.M. Mannucci Hemostatic drugs N Engl J Med 339 1998 245 253
4. P.M. Mannucci, and M. Levi Prevention and treatment of major blood loss N Engl J Med 356 2007 2301 2311
5. R. Sorensen, M.L. Hansen, S.Z. Abildstrom, A. Hvelplund, C. Andersson, and C. Jorgensen Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
6. K.P. Alexander, A.Y. Chen, M.T. Roe, L.K. Newby, C.M. Gibson, and N.M. Allen-LaPointe Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 294 2005 3108 3116
7. P. Willis, and M.D. Voeltz Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction Am J Cardiol 104 2009 34C 38C Suppl
8. J.W. Eikelboom, S.R. Mehta, S.S. Anand, C. Xie, K.A. Fox, and S. Yusuf Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
9. L. De Luca, G. Casella, M. Lettino, G. Fradella, V. Toschi, and M.R. Conte Clinical implications and management of bleeding events in patients with acute coronary syndromes J Cardiovasc Med 10 2009 677 686
10. S.V. Rao, K. O'Grady, K.S. Pieper, C.B. Granger, L.K. Newby, and F. Van de Werf Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206 (Pubitemid 41505393)
11. S.V. Rao, J.A. Eikelboom, C.B. Granger, R.A. Harrington, R.M. Califf, and J.P. Bassand Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1193 1204
12. F.A. Spencer, M. Moscucci, C.B. Granger, J.M. Gore, R.J. Goldberg, and P.G. Steg Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 116 2007 2793 2801
13. H.L. Dauerman Percutaneous coronary intervention pharmacology: from a triangle to a square J Am Coll Cardiol 51 2008 698 700
14. S.V. Rao, J.G. Jollis, R.A. Harrington, C.B. Granger, L.K. Newby, and P.W. Armstrong Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562
15. M.S. Sabatine, D.A. Morrow, R.P. Giugliano, P.B. Burton, S.A. Murphy, and C.H. McCabe Association of hemoglobin levels with clinical outcomes in acute coronary syndromes Circulation 111 2005 2042 2049
16. S.R. Hill, P.A. Carless, D.A. Henry, J.L. Carson, P.C. Hebert, and D.B. McClelland Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion Cochrane Database Syst Rev 2 2002 CD002042
17. H.G. Welch, K.R. Meenhan, and L.T. Goodnough Prudent strategies for elective red blood cell transfusion Ann Intern Med 116 1992 393 402
18. C.G. Koch, L. Li, D.I. Sessler, P. Figueroa, G.A. Hoeltge, and T. Mihaljevic Duration of red-cell storage and complications after cardiac surgery N Engl J Med 358 2008 1229 1239
19. L.M.G. van de Watering, J. Hermans, J.G. Houbiers, P.J. van den Broek, H. Bouter, and F. Boer Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial Circulation 97 1998 5562 5568
20. Y.M. Bilgin, L.M. van de Watering, L. Eijsman, M.I. Versteegh, R. Brand, and M.H. van Oers Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery Circulation 109 2004 2755 2760
21. E.C. Vamvakas, and M.A. Blajchman Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention Blood 113 2009 3406 3417
22. S. Subherwal, R.G. Bach, A.Y. Chen, B.F. Gage, S.V. Rao, and L.K. Newby Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score Circulation 119 2009 1873 1882
23. S. Schulman, Kearon C. Beyth RJ, and M.N. Levine Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 Suppl. 6 2008 257S 298S
24. J.J. Ferguson, R.M. Califf, E.M. Antman, M. Cohen, C.L. Grines, and S. Goodman Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
25. S. Yusuf, S.R. Mehta, S. Chrolavicius, R. Afzal, J. Pogue, and C.B. Granger Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
26. G.W. Stone, B.T. McLaurin, D.A. Cox, M.E. Bertrand, A.M. Lincoff, and J.W. Moses Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
27. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, and D. Dudek Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
28. L. Andersson, I.M. Nilsson, J.E. Nilehn, U. Hedner, B. Granstrand, and B. Melander Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid Scand J Haematol 2 1965 230 247
29. S. Thorsen Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids Biochim Biophys Acta 393 1975 55 65
30. D.A. Henry, A.J. Moxey, P.A. Carless, D. O'Connell, B. McClelland, and K.M. Henderson Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion Cochrane Database Syst Rev 1 2001 CD001886
31. H. Fritz, and G. Wunderer Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs Arzneimittelforschung 33 1983 479 494
32. H. Hoffmann, M. Siebeck, O. Thetter, M. Jochum, and H. Fritz Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo Adv Exp Med Biol 247B 1989 35 42
33. D.A. Fergusson, P.C. Hebert, C.D. Mazer, S. Fremes, C. MacAdams, and J.M. Murkin A comparison of aprotinin and lysine analogues in high-risk cardiac surgery N Engl J Med 358 2008 2319 2331
34. D. Henry, P. Carless, D. Fergusson, and A. Laupacis The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis CMAJ 180 2009 183 193
35. M. Cattaneo The use of desmopressin in open-heart surgery Haemophilia 14 S1 2008 40 47
36. M. Cattaneo, A.S. Harris, U. Stromberg, and P.M. Mannucci The effect of desmopressin on reducing blood loss in cardiac surgery - a meta-analysis of double-blind, placebo-controlled trials Thromb Haemost 74 1995 1064 1070
37. S.E. Fremes, B.I. Wong, E. Lee, R. Mai, G.T. Christakis, and R. Mc Lean Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding Ann Thorac Surg 58 1994 1580 1588
38. M. Levi, M.E. Cromheecke, E. de Jonge, M.H. Prins, B.J. de Mol, and E. Briët Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints Lancet 354 1999 1940 1947
39. H.R. Roberts, D.M. Monroe, and G.C. White The use of recombinant factor VIIa in the treatment of bleeding disorders Blood 104 2004 3858 3864
40. S. Butenas, K.E. Brummel, R.F. Branda, S.G. Paradis, and K.G. Mann Mechanism of factor VIIa-dependent coagulation in hemophilia blood Blood 99 2002 923 930
41. H. ten Cate, K.A. Bauer, M. Levi, T.S. Edgington, R.D. Sublett, and S. Barzegar The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor J Clin Invest 92 1993 1207 1212
42. T. Lisman, L.O. Mosnier, T. Lambert, E.P. Mauser-Bunschoten, J.C. Meijers, and H.K. Nieuwenhuis Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A Blood 99 2002 175 179
43. M. Levi, M. Peters, and H.R. Buller Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review Crit Care Med 33 2005 883 890
44. R. Altman, A. Scazziota, M. De Lourdes Herrera, and C. Gonzalez Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation J Thromb Haemost 4 2006 2022 2027
45. M.C. Poon The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders Transfus Med Rev 21 2007 223 236